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Abstract
Aiming at radiopharmaceutical application, ln
3+ complexes of the
polyaminocarboxylates TTHA, TTHA-bis(butylamide) and TTHA-bis(glucamide) were
investigated. The in vitro stability of In(TT+HA)
3- and ln(TTHA-bis(butylamide) was
evaluated by measuring the exchange of ln
3 from the complexes to transferrin and the
results were corn+pared with those for In(DTPA)-. We also performed biodistribution studies of
the three ln
3 complexes by gamma-imaging in Wistar rats and by measuring the
radioactivity in their organs. TTHA and its derivatives seem to have similar in vivo
biodistribution with prevailing renal excretion.
1. Introduction
Nuclides of indium have found widespread use in nuclear medicine. ln, a /-emitting
isotope, has nearly ideal physical characteristics (it decays by electron capture emitting 2
usable gamma photons of 173 KeV and 247 KeV with a 184% photon yield [1]). ln has a
half-life of 2.8 days which allows studies over several days with small activities administered
radioactivity [2]. It also presents suitable chemical properties for in vivo applications: only the
3+ oxidation state occurs in water and its aqueous chemistry is dominated by its strong Lewis
acidity and oxophilicity [3].
Among the chelating agents which have found applications in medicine, DTPA
(diethylenetriaminepentaacetic acid) remains one of the most used [2], because it forms
stable complexes with many cations and allows the preparation of bifunctional chelating
derivatives; it can easily be linked to high molecular weight compounds. 4In(DTPA) has been
described as an ideal agent for scintigraphic studies of the cerebrospinal fluid pathway [4,5].
Functionalization may be important to increase the selectivity of a radiotracer and to
modulate its hydrophilic/lipophilic character.
Since the biodistribution and excretion of substances injected into the blood stream are
influenced by factors like molecular size, molecular weight, charge and hydrophilicity of the
complex [6], we study in this work the in vitro and in vivo behaviour of ln complexes of the
DTPA analogue TTHA (triethylenetetraaminehexaacetic acid) and of two of its derivatives,
TTHA-bis(butylamide) and TTHA-bis(glucamide) (Fig.l) and compare it with the behaviour of
111 2 In(DTPA) . The ligands mentioned form a series of negatively charged complexes with In
3/
[7,8] with varying molecular properties.
Serum transferrin is normally only about 30% saturated with iron and retains a relatively
3+ 3+ :3"t" high capacity for binding other metal ions, namely Ga and In [9]. When In s njected n
the form of lnCI3, the metal ion is transchelated by transferrin and the radioisotope is then
found in areas of high iron uptake such as bone marrow, liver and spleen [10]. Consequently,
before molecules or biomolecules labelled with ln can be considered as valid radiotracers
in vivo, it must be shown that the chelates are thermodynamically stable or kinetically inert
towards transmetallation with transferrin.
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Fig. 1.Chemical structures of the ligands used in this study, where R OH (TTHA), NH-(n-butyl) (TTHA-
bis(butylamide), TTHABuA2), NH-(n-glucosyl) (TTHA-bis(glucamide), TTHAGluA2)
Therefore we studied the in vitro stability of 1111n(TTHA)
3- and
bis(butylamide)] and compared it with that of In(DTPA) [11].
11In[TTHA-
2. Materials and Methods
Reagents: lnCI3, CIS-Biointernational. TTHA, Sigma. TTHABuA2 and TTHAGluA2
were synthesised and characterised as described elsewhere [7,8]. ITLC-SG (Instant Thin-
Layer Chromatography-Silica Gel), Gelman Sciences, Inc.. Other reagents and solvents
were obtained either from Aldrich or Sigma and used as supplied.
2.1. In vitro stability
The in vitro stability .of In(TTHA)-
and In(TTHABuA)- was evaluated by measuring
the transchelation of ln to transferrin in blood serum as a function of time. This study was
performed by gel filtration, after appropriate time intervals, of the solutions containing
transferrin and the ln
/ complexes, using a method described in the literature [10]. A
carrier free solution of 150 1 of lnCl in 0.1 N HCI (370 MBq/g In) was mixed with 2 ml of
0.05 M sodium citrate (pH 6.5). This solution was mixed with 10 1 of a ligand solution, in
such a way that a 1:1 ligand-metal ratio was obtained. A 200 1 aliquot of this mixture was
added to 3 ml of human serum (final solution activity 1.5 mCi) and was subjected to gel
filtration (Sephadex G-25, lx15 cm column). The column was eluted with 0.01 M PBS
buffer (pH 7.4) at a flow rate of ca. 38 ml/h. Samples were taken after a dead volume of 4
rain. Activity in the samples was detected with a /well-counter. The same procedure has
been used with a transferrin solution (2x10 M). Before mixing this solution with the
complex, a NaHCOz solution was added (final HCO concentration 5 mM [11]). A 200 1
aliquot of this mixture was added to 10 t1 of an In(TTHABuA)- solution. At appropriate
time intervals, 25 !1 of this mixture was subjected to gel filtration as described above.
2.2. Gamma imaging
A gamma camera-computer system (GE 400 AC\STARPORT) was used for data
acquisition and pre-processing. Data processing and display were performed with a CityDesk
software developed for these experiments. IBM AT compatible computer usingln3._ Gamma images for the three complexes studied in this work and for In(DTPA)- as comparison, were obtained using 300-400 g Wistar rats (groups of four animals with
111 2 111 111 3 In(DTPA) and In(TTHAGluA)-and groups of eight animals in the case of In(TTHA)
111 and In(TTHABuA)-. The rats were anaesthetised via intramuscular injection with ketamine
10 an c
111 3+ (50 mg/ml) ! chlorpromazine (2.5%) :3) d a. 150 lCi of. In complexes were
injected into the femoral vein (previously catheterised with an heparinised abocat 26G) or
in the tail vein. The animals were then positioned in dorsal or ventral decubitus over the
detector. Image acquisition was initiated immediately after radiotracer injection.
Sequences of 180 images (360 in the cases of In(TTHA) and In(TTHABuA)), of ten
seconds each, were acquired to 64x64 matrices. Blood samples were taken during the
dynamic acquisition and subsequently counted in a y well-counter.
The efficiency of labelling of the ligands with ln
3/ was checked at 24 h intervals by
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chromatography. This study was performed with an ITLC-SG/butanone system, analysing 10 !1
of each solution of the complex. Gamma images of the chromatograms were obtained to
128xt28 matrices with a total acquisition time of 15 min. For all the complexes the
percentage of bound ln
/ was nearly 100%.
To analyse the transport of radiotracer over time, three regions of interest were drawn on
the image files, corresponding to the thorax, liver and left kidney. From these regions, time-
activity curves were obtained using home-made software.
In addition, static data were acquired at 24, 48 and 72 h after the radiotracer injection.
2.3. Biodistribution experiments
Two groups of four animals were injected with ca. 100 lCi of In(.DTPA)
2 and
In(TTHAGluA2)-and sacrificed 2 h later. The majors organs were removed, weighted and
counted in a y well-counter. Similar biodistribution studies were also performed with the rats
used in the gamma experiments referred in the previous section sacrificed at 72 h after
injection with all the ln chelates studied in this work.
3. Results and Discussion
3.1. In vitro stability
The preliminary results on the in vitro stability of In(TTHA)z and in(TTHABuA2)-in
blood serum and in a transferrin solution are summarised in Table 1. Literature data on
In(DTPA) [12] are included for comparison. The presently studied complexes dissociate
more rapidly than In(DTPA)-. This is in agreement with published thermodynamic stability
data for the ligands and forthe transferrin complexs [pM (In(if)) = 20.4, pM (In(TTHA)z) = 22.88,
pM (In(TTHABuA)-) =19.43 and pM (In(DTPA)") = 24.72] [7,13], which reflect the structures of
the chelates in solution [7,14].
Table 1.Time dependence of the percent dissociation of the 111In-chelates in blood serum and in a
transferrin (tf) solution.
T]’me(h) % Dissociation
TTHA TTHABuA2 ’DTPA
blood serum blood serun
Blood serum ff solution
0.30 1.64 0.37
2.36 7.54 1.5 [12]
48 5.43 3.26 <3.0 [12]
3.2. Images and biodistribution data
Fig.2 represents the averaged time-activity curves, obtained from the dynamic
acquisitions for each region of interest. The curves were smoothed and normalised for the
maximum activity of each one. The complexes studied undergo an early retention, both in
kidneys and in liver and spleen. These results contrast with the time-activity curves obtained
for the In(DTPA) complex, where the liver-spleen curve is similar to the thorax curve,
corresponding to blood activity. The thorax curves for the In(TTHA), In(TTHABuA)-and
In(TTHAGluA) chelates also correspond only to blood activity.
The scintigraphic images at 30 minutes, 24 h and 72 h after ln chelates injection in
rats are illustrated in Fig.3. In the early images, and for all the complexes, the activity is
preferentially Iocalised in kidneys. In some of these images the injection site is also observed.
After 24 h the activity was spread out and was then Iocalised mainly in the abdominal region
and in the kidneys. The 72 h images show the same behaviour, but it is particularly
noticeable that In(TTHAGluA) has higher uptake by the liver-spleen region.
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Fig. 2. Time-activity curves for a)lllln(TTHABuA2) b)IIn(DTPA)
2
(b)
The biodistribution results (in percent of injected dose per gram of organ) obtained at 2
h and 72 h are shown in Fig. 4 and agree with the gamma-imaging. It can be noticed that in
contrast to In(DTPA)-,In(TTHAGluA)-has low tissue specificity and undergoes both renal
and hepatobiliary clearance. The biodistribution results obtained at 72 h (Fig.4) show that for
all the complexes the activity is preferentially Iocalised in the kidneys. This indicates renal
excretion of the chelates, which is consistent with their structure, molecular weight and
hydrophilicity.
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i In(TTHAGluA2)- Fill :3. Scintigraphic images at 30 min and 48 h (from top to bottom) after injection with a) In(TTHA) and
b)
The high late retention of the 111n complexes of TTHA, TTHABuA2 and TTHAGluA2 by
the reticulo-endothelial system may be related with the formation of colloidal particles of
indium hydroxide associated with partial demetallation of the chelates [15], in addition to the
natural occurrence of the complexes. High radioactivity levels in blood after 30 minutes
suggest that the complexes may bind to serum proteins, perhaps albumin, but further in vitro
studies are necessary to validate this hypothesis.
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Biodistribution of 1111n metal complexes in rat tissues at a) 2 h and b) 72 h after injection of the
chelates.
None of the complexes passes through the blood-brain barrier, as expected for high
molecular weight and non-lipophilic complexes. There is no evidence of bone marrow
accumulation, which is seen when the indium-transferrin complex is formed [16].
In conclusion TTHA and its derivatives have similar in vivo behaviour and the linkage of
the lipophilic side chains in the case of TTHABuA2 and TTHAGluA2 does not seem to
influence the biodistribution and clearance of these complexes.
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